Novo Nordisk says obesity drug trial confirms weight loss
The company presented the result as confirmation of the weight-loss effect seen in its earlier obesity work.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 11 15:01 ETSource: BusinessWorld Online
The wire
- 01Novo Nordisk reported that a trial of its obesity drug confirmed weight loss, according to the company.
- 02Clinicians and telehealth operators tracking incretin supply and labelling watch Novo readouts for signals on future indications and uptake.
- 03The report rests on the company's own characterisation; magnitude of weight loss, dosing and endpoint detail would need the full trial data.
From the source
Read at bworldonline.comnovo nordisk says obesity drug trial confirms weight loss
